Veeva Systems Inc (VEEV)
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides Veeva Data Cloud, such as Veeva OpenData, a customer reference data solution; Veeva Link, which provides deep data; Veeva Compass, which includes de-identified and longitudinal patient data; and Veeva CRM Pulse that provides access and multichannel engagement metrics. In addition, the company offers Veeva Development Cloud consisting of Veeva Clinical Platform, which advances clinical trial execution; Veeva Clinical Data Management that helps sponsors and CROs design and run trials; Veeva Safety, which unifies systems and processes; Veeva RIM that provides regulatory information management capabilities, as well as Veeva Quality Cloud, which is used by the life sciences and consumer products industries; and Veeva Business Consulting services. Further, it provides professional and support services, including implementation and deployment planning, and project management; requirements analysis, solution design, and configuration; systems environment management and deployment; services focused on advancing or transforming business and operating processes; technical consulting services on data migration and systems integrations; training; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.
- Ticker
- VEEV
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Health Information Services
- Market cap
- $49.15B
- 52-week range
- $148.05 - $325.99
Valuation
- Share price
- $303.73 (close of Nov 6, 2026)
- P/E (TTM)
- 48.99x
- Price to book
- 6.61x
- Price to free cash flow
- 29.51x
- Enterprise value
- $47.49B
- Book value per share
- $45.92
Price performance
| Period | Change |
|---|---|
| 1 day | -2.05% |
| 5 days | -2.95% |
| 1 month | +7.14% |
| 3 months | +39.45% |
| 6 months | +81.49% |
| Year to date | +36.06% |
| 1 year | +4.30% |
| 3 years | +54.85% |
| 5 years | -4.73% |
| 10 years | +709.08% |
| All time | +717.36% |
Short interest
- As of
- Oct 15, 2026
- Short % of float
- 2.84%
- Shares short
- 4.20M
- Days to cover
- 2.90
- Change since prior report
- -14.14%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed VEEV trades
Byron Donalds · Robert Bresnahan
Super investors holding VEEV
Terry Smith (Fundsmith LLP) · Francois Rochon (Giverny Capital Inc) · Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates) · Vulcan Value Partners (Vulcan Value Partners, LLC) · Hillman Capital (Hillman Capital Management, Inc)
Profitability and growth
- Return on equity
- 12.60%
- Return on invested capital
- 8.63%
- Return on assets
- 10.12%
- Return on capital employed
- 12.48%
- Gross margin
- 75.53%
- Net margin
- 28.44%
- EBITDA margin
- 28.68%
- Revenue growth
- 16.34%
- Net income growth
- 27.27%
- Free cash flow growth
- 29.83%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 3.39%
- Current ratio
- 5.46x
- Net debt to EBITDA
- -1.54x
Latest reported year
- Period end
- Jan 31, 2026
- Fiscal year
- 2026
- Revenue
- $3.20B
- Cost of revenue
- $782.02M
- Gross profit
- $2.41B
- EBITDA
- $916.37M
- Net income
- $908.91M
- Earnings per share
- $5.55
- Research and development
- $767.39M
- Shares outstanding
- 163.67M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2026-01-31 | $3.20B | $2.41B | $908.91M | $5.55 |
| 2025-01-31 | $2.75B | $2.05B | $714.14M | $4.41 |
| 2024-01-31 | $2.36B | $1.69B | $525.71M | $3.27 |
| 2023-01-31 | $2.16B | $1.55B | $487.71M | $3.14 |
| 2022-01-31 | $1.85B | $1.35B | $427.39M | $2.79 |
| 2021-01-31 | $1.47B | $1.06B | $380.00M | $2.52 |
| 2020-01-31 | $1.10B | $800.71M | $301.12M | $2.04 |
| 2019-01-31 | $862.21M | $616.93M | $229.83M | $1.59 |
| 2018-01-31 | $690.56M | $479.14M | $151.18M | $1.08 |
| 2017-01-31 | $550.54M | $376.86M | $77.57M | $0.57 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2026-01-31 | 75.53% | 28.44% | 12.60% | 8.63% |
| 2025-01-31 | 74.53% | 26.00% | 12.24% | 8.23% |
| 2024-01-31 | 71.35% | 22.24% | 11.32% | 7.81% |
| 2023-01-31 | 71.72% | 22.63% | 13.12% | 11.59% |
| 2022-01-31 | 72.79% | 23.09% | 14.68% | 14.18% |
| 2021-01-31 | 72.09% | 25.94% | 16.77% | 15.62% |
| 2020-01-31 | 72.52% | 27.27% | 18.08% | 15.91% |
| 2019-01-31 | 71.55% | 26.66% | 18.57% | 17.29% |
| 2018-01-31 | 69.38% | 21.89% | 16.68% | 15.82% |
| 2017-01-31 | 68.45% | 14.09% | 11.44% | 11.19% |
Cash and debt by year
| Period end | Cash |
|---|---|
| 2026-01-31 | $1.42B |
| 2025-01-31 | $1.12B |
| 2024-01-31 | $703.49M |
| 2023-01-31 | $886.47M |
| 2022-01-31 | $1.14B |
| 2021-01-31 | $730.50M |
| 2020-01-31 | $476.73M |
| 2019-01-31 | $550.97M |
| 2018-01-31 | $761.96M |
| 2017-01-31 | $518.87M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2026-01-31 | $1.42B | $472.70M |
| 2025-01-31 | $1.09B | $437.35M |
| 2024-01-31 | $911.34M | $393.73M |
| 2023-01-31 | $780.47M | $351.91M |
| 2022-01-31 | $764.46M | $234.64M |
| 2021-01-31 | $551.25M | $185.00M |
| 2020-01-31 | $434.26M | $115.91M |
| 2019-01-31 | $302.39M | $76.42M |
| 2018-01-31 | $223.81M | $54.05M |
| 2017-01-31 | $137.09M | $40.80M |
Investor relations
Next earnings report
- Next confirmed report
- Nov 19, 2026
- Consensus EPS estimate
- $1.68
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-08-26 | Jul 2026 | $1.62 |
| 2026-06-03 | Apr 2026 | $1.55 |
| 2026-03-04 | Jan 2026 | $1.36 |
| 2025-11-20 | Oct 2025 | $1.36 |
| 2025-08-27 | Jul 2025 | $1.34 |
| 2025-05-28 | Apr 2025 | $1.20 |
| 2025-03-05 | Jan 2025 | $1.02 |
| 2024-12-05 | Oct 2024 | $1.05 |
Filings and sources
- Company website
- veeva.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
HealthEquity, Inc. (HQY) · Molina Healthcare, Inc. (MOH) · HCA Healthcare, Inc. (HCA) · Centene Corp (CNC) · DaVita Inc. (DVA) · Humana Inc (HUM) · Universal Health Services Inc (UHS) · Cigna Group (CI)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades